The FDA looks at the benefit/risk profile of Essure. And, what place does MRI have in breast cancer treatment? Plus: A look at ovarian stimulating agents.
News, a surgical video, and links related to infertility and fertility preservation.
Less may be more when it comes to surgical management.
A look at the science behind 3-parent embryos and the legal complexities that may follow.
A form of assisted reproductive technology that could make it possible for women with mutations in mitochondrial DNA to give birth to children free of mitochondrial disease has been approved by UK’s House of Commons. A Food and Drug Administration (FDA) committee is considering granting similar approval for use of the technique—known as oocyte modification or three-parent gene therapy—in the United States.
Results of a retrospective cohort study show that use of intracytoplasmic sperm injection is on the rise but cast doubt on whether the technology is improving reproductive outcomes. Brian Levine, MD, MS provides commentary.
Unlike with in vitro fertilization, it appears that uterine contractions may increase the chance of a successful intrauterine insemination (IUI), according to a new study.
A small study by investigators from Harvard University suggests that cryopreserved embryo transfer (CET) is a strong independent risk factor for placenta accreta in women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).
First-trimester exposure to maternal estradiol may increase risk of thyroid dysfunction in offspring conceived via in vitro fertilization (IVF), according to a study in Fertility & Sterility.
An aromatase inhibitor was safe for use in ovarian stimulation but produced fewer live births than a standard clomiphene citrate (CC) regimen, according to results of a multicenter trial.